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The most frequent ocular adnexal tumors and simulating lesions are lymphoproliferative disorders (LPDs), including malignant
lymphomas and orbital inﬂammation with lymphoid hyperplasia or inﬁltration. IgG4-related orbital inﬂammation (IgG4-ROI)
often involves lacrimal glands and other orbital tissues and is an important diﬀerential diagnosis. The present study evaluated
clinical aspects of IgG4-ROI in a case series of orbital LPD. Sixty-two consecutive cases of orbital LPD, pathologically diagnosed
from November, 2004, through March, 2011, were investigated. Histological types were 22 cases with MALT lymphoma, 11 cases
with diﬀuse large B-cell lymphoma (DLBCL), 3 cases with other malignant lymphomas, 16 cases with IgG4-ROI, and 10 cases
with non-IgG4-ROI. Ages of the IgG4-ROI group (56 ± 10yrs) were signiﬁcantly lower than the MALT lymphoma (71 ± 12yrs)
and DLBCL (75±14yrs) groups. Orbital lesions other than lacrimal glands were present in six cases including extraocular muscle
swelling, mass lesions surrounding the optic nerve, and supraorbital and infraorbital nerves enlargements. Although none of the
malignant lymphomas were related to IgG4, previous evidence suggested that malignant lymphomas can arise from IgG4-ROI.
Based on this study (26%) and another report (33%), it is likely that nearly a quarter of orbital LPD are IgG4-ROI.
1.Introduction
The most frequent tumors and simulating lesions in ocular
adnexa are lymphoproliferative disorders (LPDs), including
malignant lymphomas and orbital inﬂammation with lym-
phoid hyperplasia or inﬁltration, some of which are his-
torically called “orbital pseudotumors.” In Japanese studies,
Goto [1] reported that the rate of LPD among 409 cases
with orbital tumors and simulating lesions was 43%, while
Ohtsuka et al. [2] described that the rate was 49% out of 213
cases. In the United States, LPD is a common orbital disease
although the rate seems to be somewhat lower: 24% of LPD
out of 703 cases with orbital lesions was reported by Shields
et al. [3], and 26% of LPD out of 268 cases was reported by
Shinder et al. [4].
When patients with suspected orbital LPD are encoun-
tered, tissue biopsy is preferred since image examinations
alone cannot distinguish inﬂammatory lesions from malig-
nant lymphomas. Pathological examination can also detect
whether the lesion is related to IgG4 or not. IgG4-related
disease (IgG4-RD) often involves lacrimal glands, which is
nowknownasIgG4-relatedMikulicz’sdisease[5,6]orI gG4-
related dacryoadenitis [7, 8] by many recent reports over
several years. Recently, it was also elucidated that IgG4-
related orbital inﬂammatory lesions include other ocular
adnexal tissues such as extraocular muscles [9]a n dp e r i o r -
bital membrane [10]. Therefore, IgG4-RD is a diﬀerential
diagnosis in orbital LPD. The question is then raised as to
what percentage of orbital LPD is related to IgG4. In this
study, an orbital LPD case series was investigated and clinical2 International Journal of Rheumatology
aspects of IgG4-related orbital lymphoproliferative disorders
were evaluated.
2. Patientsand Methods
In Kanazawa University Hospital in Japan, a 47-year-old
woman with IgG4-immunopositive histopathology and an
elevated serum IgG4 level of 1000mg/dL was diagnosed as
a ﬁrst case of IgG4-related dacryoadenitis in November, 2004
[8]. From that time through March, 2011, sixty-two cases
( 2 7m e na n d3 5w o m e n ;m e a na g e ,6 6± 14 yrs; range 32–
89 yrs) were pathologically diagnosed with orbital lympho-
proliferative diseases (LPD) from surgical samples of ocular
adnexal tissue. The two main categories of orbital LPD were
malignant lymphomas and orbital inﬂammations: the latter
includedreactivelymphoidhyperplasia,lymphoidinﬁltrated
lesions, and inﬂammatory pseudotumor. This consecutive
62 case series was investigated retrospectively. Conjunctival
lesions were not enrolled in this study because conjunctival
involvement in IgG4-RD has never been experienced in
previous reports [9, 11] or in the author’s institution.
Intraocular lymphoma belongs to CNS lymphoma and thus
was also excluded in this study. In most cases, immunoglob-
ulin heavy chain gene rearrangement in surgical samples
was also examined to support the diﬀerential diagnosis
of malignant lymphoma. Diagnostic criterion for positive
IgG4-immunostaining in orbital tissue (IgG4-related orbital
disease) was either (1) the ratio of IgG4-positive cells to IgG-
positive cells (IgG4+/IgG+ cells) was more than 40% [12],
or (2) the number of IgG4-positive cells was more than 30
per high power microscopy ﬁeld [13]. Mouse monoclonal
antibody anti-human IgG4 (05-3800, ZYMED, USA) and
rabbit polyclonal antibody anti-human IgG (A0423, Dako,
USA) were used for immunostaining. Serum IgG and IgG4
were measured in all of the cases with an IgG4-positive
pathologicaldiagnosis.IgG4-relatedorbitallesionsincluding
lacrimalglandswelling,extraocularmuscleenlargement,and
other mass lesions were evaluated using computed tomogra-
phy (CT) and/or magnetic resonance imaging (MRI).
3. Results
Histological types of the 62 orbital LPD were 22 cases
(35%)withextranodalmarginalzonelymphomaofmucosa-
associated lymphoid-tissue type (MALT lymphoma), 11
cases (18%) with diﬀuse large B-cell lymphoma (DLBCL),
3 cases (5%) with other malignant lymphomas (1 mantle
cell lymphoma, 1 NK/T cell lymphoma, 1 small lym-
phocytic lymphoma), 16 cases (26%) with IgG4-related
orbital inﬂammation (IgG4-ROI), and 10 cases (16%) with
non-IgG4-related orbital inﬂammation (non-IgG4-ROI)
(Figure 1). None of the malignant lymphomas showed a
relationship with IgG4 in this case series. Figure 2 depicts
the ages of the four groups of DLBCL, MALT lymphoma,
IgG4-ROI, and non-IgG4-ROI. Ages of the IgG4-ROI group
averaged 56 ± 10 yrs, which was signiﬁcantly lower than
those of the MALT lymphoma (71 ± 12 yrs, P = 0.00027 in
aS t u d e n t ’ st-test) and DLBCL (75 ± 14 yrs, P = 0.00107)
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Figure 1: Breakdown of diagnosis in orbital lymphoproliferative
disorders. Patients were a consecutive 62 case series with or-
bital lymphoproliferative disorders pathologically diagnosed from
November, 2004, to March, 2011, in Kanazawa University Hos-
pital, Japan. Cases with conjunctival and intraocular lesions were
excluded. MALT lymphoma is an abbreviation for extranodal mar-
ginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
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Figure 2: Ages of orbital lymphoproliferative disorders. Each plot
depicts age at diagnosis in groups of MALT lymphoma, DLBCL
(diﬀuse large B-cell lymphoma), IgG4-related orbital inﬂammation
and non-IgG4-related orbital inﬂammation. Closed and open plots
represent men and women, respectively.
groups. There were no signiﬁcant age diﬀerences between
other combinations of the four groups.
Clinical data of sixteen cases of IgG4-ROI are summa-
rized in Table 1, which were sorted in ascending order of
serum IgG4 level. The age ranged between 41 to 76 yrs
(mean ± SD; 56 ± 10 yrs, median; 58 yrs), and there was
no sex diﬀerence (8 men and 8 women). These cases except
one(number1,detailedinthediscussion)wereaccompanied
by elevated serum IgG4 concentration (549 ± 293mg/dL,International Journal of Rheumatology 3
Table 1: Clinical data in 16 cases with IgG4-related orbital disease.
Case
number Age Sex Orbital
lesions Lesions other than orbit Serum IgG
(mg/dL)
Serum IgG4
(mg/dL)
IgG4/IgG
(%)
IgG4 +
cells /HPF
Serum IgE
(IU/mL) Therapy
1 62 F LG None 1690 29 2 43 14 None
2 66 M LG SG 1960 164 8 143 1621 None
3 56 F LG Lung lesion 1671 194 12 46 254 Steroid
4 46 F LG, EOM SG, retroperitoneal ﬁbrosis 1350 209 15 92 170 Steroid
5 41 F LG Sinusitis 1554 260 17 62 178 None
6 53 F LG SG 2260 359 16 58 611 Steroid
76 5 M LG, EOM,
ION
Sinusitis, submandibular
lymphadenopathy 1448 404 28 98 3374 Steroid
86 0 M
LG, EOM,
OPN, SON,
ION
SG, neck skin nodule 1220 463 38 82 4608 Steroid
9 64 F LG SG, neck lymph nodes TB 1820 486 27 83 90 Steroid
10 66 M LG S G ,l u n gl e s i o n ,a x i l l a r y
lymphadenopathy 1900 575 30 48 151 Steroid
11 44 M LG, OPN,
ION None 1322 599 45 63 351 Steroid
12 76 F LG Nephritis 2860 769 27 58 428 Steroid
13 60 M LG SG, 1952 886 45 48 575 Steroid
14 45 M LG, EOM,
ION Lung lesions, sinusitis 2260 914 40 74 72 Steroid
15 52 M LG SG 3440 949 28 50 973 Steroid
16 47 F LG, SON,
ION SG 2350 1000 43 55 183 Steroid
Normal range 870–1700 <135 <7 <10 <250
LG: lacrimal gland, EOM: extraocular muscle, OPN: optic nerve, SON: supraorbital nerve, ION: infraorbital nerve, SG: salivary gland.
n = 15, normal range < 135mg/dL) and an increased ratio
of serum IgG4/IgG (28 ± 12%, n = 15, normal range < 7%).
In 9 patients, the serum IgE was also elevated. In all 16 cases,
diagnosis was made by lacrimal gland biopsy. In pathology,
these were characterized by lymphoplasmacytic inﬁltration,
forming lymphoid follicles (germinal center) and sclerosing
ﬁbrosis [8]. IgG4-positive plasma cells were observed around
lymphoid follicles and in intraglandular areas [8]. Orbital
lesions other than lacrimal glands were detected by MRI in
six cases (cases numbers 4, 7, 8, 11, 14, and 16 in Table 1)
as shown representatively in Figure 3. Swollen extraocular
muscles were seen in four cases (numbers 4, 7, 8 and 14).
Supraorbital nerve (frontal nerve), and/or infraorbital nerve
enlargementswereobservedin4cases(numbers7,8,11,and
14). A mass lesion surrounding the optic nerve was detected
in two patients (numbers 8 and 11).
Steroid therapy wasperformedfor allthe IgG4-ROI cases
except three patients because their eyelid swellings decreased
in size after biopsy surgery (case numbers 1, 2, and 5)
and because of normal serum IgG4 (case number 1) and
diabetes mellitus (case number 2). Eleven cases underwent
oral prednisolone tapering therapy with an initial dose of
20, 30, or 40mg per day. In two cases with diabetes mellitus,
lowerdosesoforalprednisolone(10mgdailyincasenumber
10 and 8mg daily in case number 15) were administered
initially and reduced to a maintenance dose. All of the
11 cases essentially responded well to initial doses of oral
prednisolone, but in 5 cases (numbers 4, 8, 10, 11, and 14)
ocular symptoms such as eyelid swelling deteriorated during
tapering, and thus increase in the dosage was required. In
case number 11 with retrobulbar mass (Figure 3(c)), oral
prednisolone therapy alone (30mg daily initially) failed to
diminish his exophthalmos, and then intravenous methyl-
prednisolone pulse (500mg for 3 days) was additionally
performed three times.
4. Discussion
In this study, none of the malignant lymphoma cases was
related to IgG4. However, some previous reports suggested
that orbital malignant lymphomas can be related to IgG4.
Cheuk reported three cases of ocular adnexal lymphoma
(2 MALT lymphoma and 1 follicular lymphoma) arising in
IgG4-related dacryoadenitis, and that the rate of transfor-
mation of malignant lymphoma in the background of IgG4-
ROI was approximately 10% [12]. Sato et al. ﬁrst detected
IgHgenerearrangementintwocasesofocularadnexalIgG4-
related disease [11] and later reported seven patients with
ocular adnexal MALT lymphoma arising from IgG4-related
orbitaldisease[14].Ontheotherhand,hedescribedacaseof
IgG4-producing MALT lymphoma of the lymph node [15].
Also in the orbital region, Oyama reported a case of IgG4-
expressing MALT lymphoma in the lacrimal gland [16].
Based on these ﬁndings, there could be two possibilities of4 International Journal of Rheumatology
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Figure 3:RepresentativecaseswithIgG4-relatedorbitalinﬂammatorylesionsotherthanlacrimalglands.(a)Enlargementsintheleftinferior
rectus muscle and infraorbital nerve (arrow) in a 65-year-old man with a serum IgG4 of 404mg/dL (case number 7 in Table 1). (b) Swelling
of the left superior and lateral rectus muscles, a mass lesion around the left optic disc (arrow), and enlargements of the left supraorbital
nerve and the right infraorbital nerve (arrow heads) were seen in a 60-year-old man with a serum IgG4 of 463mg/dL (case number 8).
(c) Mass lesion around the right optic disc was observed in a 44-year-old man with a serum IgG4 of 599mg/dL (case number 11). (d)
Bilateral supraorbital nerve enlargements (arrows) and right infraorbital nerve enlargement were observed in a 47-year-old woman with a
serum IgG4 of 1000mg/dL (case number 16). Magnetic resonance images are T1-weighted in (b) and (d) and T2-weighted in (a) and (c).
orbital MALT lymphoma arising from preexisting IgG4-ROI
and de novo IgG4-positive orbital MALT lymphoma [12].
In any case, orbital biopsy should be mandatory to evaluate
malignancy before treatment even if serological examination
already detected elevated serum IgG4.
There is no doubt that IgG4-ROI most frequently
involvesthelacrimalgland,whichisreportedasIgG4-related
dacryoadenitis and Mikulicz’s disease [5–8]. In addition,
lesions of IgG4-ROI other than the lacrimal glands were
reported previously. Sato et al. reported that orbital masses
other than the lacrimal gland were detected in 7 out of 21
cases with IgG4-ROI [11]. Kubota et al. reported a case with
bilateralmultipleextraocularmuscleenlargement[9].Mehta
et al. presented a case of IgG4-ROI with enlargement of
theinfraorbitalcanalandperiorbitalmembraneinvolvement
[10]. Similar lesions were observed in the present case series
of IgG4-ROI (Figure 3). In addition, mass lesions around the
optic nerve were seen in two cases, indicating that involve-
ment of the optic nerve sheath may not be rare in IgG4-ROI.
Among 16 cases of IgG4-ROI, one patient (case number
1 )p r e s e n t e dn o r m a ll e v e l so fs e r u mI g G 4 .I nt h i sc a s e ,t h e
ratio of IgG4+/IgG+ cells in immunohistochemistry was
around 30%, somewhat lower than values in diagnostic
criteria [6, 12], but IgG4-positive cells were more than 30 per
high power microscopy ﬁeld. The pathological ﬁndings that
lymphoplasmacytic inﬁltration with germinal centers and
dense sclerosing ﬁbrosis was characteristic for IgG4-ROI. So
far,wecannotresolvethereasonforthisdiscrepancybetween
pathological and serological ﬁndings. However, Kubota
previously reported a patient with an inverse discrepancy
who had negative ﬁndings on the IgG4 immunostaining
despite presumably typical IgG4-ROI with elevated serum
IgG4 [9].
The rate of IgG4-RD in 62 cases with orbital LPD was
26% in this study and was reported to be 33% out of 58
orbitalLPDcasesfromanotherJapaneseinstitute[17].Thus,
it is likely that nearly a quarter of orbital lymphoproliferative
disorders are estimated to be related to IgG4. Further
multicenter studies will be required to conﬁrm this rate and
to evaluate the frequency and location of IgG4-ROI other
than the lacrimal glands.
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